An open-label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (Q3W) in patients with locally advanced and/or metastatic breast cancer

Trial Profile

An open-label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (Q3W) in patients with locally advanced and/or metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2009

At a glance

  • Drugs Capecitabine; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 19 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top